Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial

Phase 3 Unknown Shahid Beheshti University of Medical Sciences

RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of intravitreal injection of bevacizumab alone versus bevacizumab combined with triamcinolone for treatment of refractory diabetic macular edema.

Timeline

Start: 2005-11
Primary completion: —
Completion: 2006-09

Outcome

Met primary endpoint

paper Central macular thickness was reduced significantly in both the IVB and IVB/IVT groups. PMID 17917738 ↗

paper There was a significant difference between the IVB and control groups (P = 0.012) and between the IVB/IVT and control groups (P = 0.022). PMID 17917738 ↗

Publications

Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, Soheilian M, Keshavarzi G, Mohebbi MR. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2008 Apr;246(4):483-9. doi: 10.1007/s00417-007-0688-0. Epub 2007 Oct 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	1.25 mg	Intravitreal
Subject	Triamcinolone	Other / unclassified	2 mg	Intravitreal